This week was ruled by cancer data presentations at the annual meeting of the American Society of Clinical Oncology (“ASCO”) in Chicago by pharma bigwigs like Bristol Myers BMY, Merck MRK and Roche RHHBY among others. In other news, Lilly’s LLY new migraine drug, Emgality and Merck’s antibacterial medicine Zerbaxa were approved by the FDA for new indications.
Recap of the Week’s Most Important Stories
Update from ASCO: Merck presented data from several cancer studies of its PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza.
It presented follow-up data from lung cancer studies on Keytruda. Data from the phase Ib KEYNOTE-001 study (n=550) showed that five-year overall survival (OS) rates for Keytruda were 23.2% in treatment-naïve lung cancer patients and 15.5% in previously treated lung cancer patients. Historically, the